ALXN
$108.37
Alexion Pharm
$2.48
2.34%
ALXN
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $2.26
Revenue:  $1.27 Bil
Wednesday
Jan 22
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, October 23, 2019

What do you expect when ALXN reports earnings?
Beat
Meet
Miss

Where is ALXN's stock price going from here?
Up
Flat
Down
Stock chart of ALXN
Analysts
Summary of analysts' recommendations for ALXN
Score
Grade
Pivots
Resistance
$111.87
$110.23
$109.30

$107.66

Support
$106.73
$105.09
$104.16
Tweet
Growth
Description
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.
Peers
IncyteExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex